MAPT and Mental deterioration: Importantly, coupled with the current ATN classification system, which is based on Amyloid (Aβ42, Aβ42/Aβ40), Tau (p-Tau181, p-Tau217), and neurodegeneration (t-Tau, NfL), and neuroimaging to assess WM atrophy and other pathologies, exosome biomarkers of WM degeneration could help to further assess the risk of cognitive decline in relation to disease staging [4,73].